Miss Abbey Begen
- Affiliate (School of Chemistry)
email:
Abbey.Begen@glasgow.ac.uk
Keltic Pharma Therapeutics, The ARC, University of Glasgow, Glasgow, G11 6EW
The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Clarity helps us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
email:
Abbey.Begen@glasgow.ac.uk
Keltic Pharma Therapeutics, The ARC, University of Glasgow, Glasgow, G11 6EW
Brettell, S. B. et al. (2024) Targeting PfCLK3 with covalent inhibitors: a novel strategy for malaria treatment. Journal of Medicinal Chemistry, (doi: 10.1021/acs.jmedchem.4c01300) (PMID:39441986) (Early Online Publication)
Brettell, S. B. et al. (2024) Targeting PfCLK3 with covalent inhibitors: a novel strategy for malaria treatment. Journal of Medicinal Chemistry, (doi: 10.1021/acs.jmedchem.4c01300) (PMID:39441986) (Early Online Publication)